MYL Mylan N.V.

0  0%
Previous Close 37.67
Open 37.74
Price To book 1.81
Market Cap 20.11B
Shares 535,497,000
Volume 3,634,433
Short Ratio 3.67
Av. Daily Volume 5,844,340

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date October 9, 2017.
Neulasta biosimilar
PDUFA date September 7, 2017.
Trastuzumab biosimilar

Latest News

  1. Glaxo Stock Slumps as Investors Eye Advair Generics
  2. India's antitrust watchdog orders probe into Roche cancer drug
  3. ETFs with exposure to Mylan NV : April 25, 2017
  4. Kmart Pharmacy sharply cuts price of Adrenaclick, competitor to EpiPen anti-allergy device
  5. Kmart Pharmacy lowers price of epinephrine auto-injector pens
  6. K-Mart to Sell Cheaper EpiPen Alternative
  7. Mylan NV :MYL-US: Earnings Analysis: 2016 By the Numbers : April 24, 2017
  8. Mylan Tried to ‘Squelch’ EpiPen Rival, Sanofi Says in Lawsuit
  9. Sanofi Sues Mylan Over EpiPen Practices
  10. Sanofi files U.S. antitrust lawsuit against Mylan over EpiPen
  11. Sanofi has filed an antitrust suit against Mylan alleging 'illegal conduct' to prevent EpiPen competition
  12. The Scariest Prescription Drug Price Chart You'll Ever See
  13. 1 Current and 1 Former Healthcare CEO Who Deserve Far More Flak Than United Airlines' Oscar Munoz
  14. Mylan Launches Generic Trilafon Tablets
  15. The Billionaire And The Drug Price-Fixing Scandal
  16. Pharma Stock Roundup: Merck Gets CRL for Label Expansion Effort, Roche Cancer Drug Tops
  17. Cramer's lightning round: This pharma stock is suffering a 'death of a thousand cuts'
  18. Mylan Down on FDA Warning Letter to Manufacturing Facility
  19. Early movers: UAL, WFM, LULU, MYL, WMT, PEP & more
  20. Mylan Says No Supply Issues Related To FDA Warning At India Plant